Maintenance treatment of advanced non-small-cell lung cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology

Lung Cancer

Volumn 76, Issue 3, 2012, Pages 269-279

  Gridelli, Cesare ^a   de Marinis, Filippo ^b   Di Maio, Massimo ^c   Ardizzoni, Andrea ^d   Belani, Chandra P ^e   Cappuzzo, Federico ^f   Ciardiello, Fortunato ^g   Fidias, Panagiotis ^h   Paz Ares, Luis ⁱ   Perrone, Francesco ^c   Pirker, Robert ^j   De Petris, Luigi ^k   Stahel, Rolf ^l  

^a S G MOSCATI HOSPITAL   (Italy)

^b SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d UNIVERSITY HOSPITAL OF PARMA   (Italy)

^e PENN STATE CANCER INSTITUTE   (United States)

^f Civil Hospital   (Italy)

^g SECOND UNIVERSITY OF NAPLES   (Italy)

^h MASSACHUSETTS GENERAL HOSPITAL   (United States)

ⁱ HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^j MEDICAL UNIVERSITY OF VIENNA   (Austria)

^k KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^l UNIVERSITY HOSPITAL ZURICH   (Switzerland)

more..

Author keywords

Bevacizumab; Cetuximab; Docetaxel; Erlotinib; Gefitinib; Gemcitabine; Maintenance; Non small cell lung cancer; Pemetrexed

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; GEMCITABINE; IFOSFAMIDE; MITOMYCIN; NAVELBINE; PACLITAXEL; PEMETREXED; PLATINUM DERIVATIVE; VASCULOTROPIN ANTIBODY;

ADVANCED CANCER; ANEMIA; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CLINICAL PROTOCOL; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; HEALTH CARE COST; HEALTH CARE ORGANIZATION; HUMAN; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PATIENT COUNSELING; PATIENT SELECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RASH; REVIEW; RISK BENEFIT ANALYSIS; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CONSENSUS DEVELOPMENT CONFERENCES AS TOPIC; HUMANS; LUNG NEOPLASMS; MAINTENANCE CHEMOTHERAPY; NEOPLASM STAGING; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84860537353     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2011.12.011     Document Type: Review

References (34)

1. Azzoli C.G., Baker S., Temin S., Pao W., Aliff T., Brahmer J., et al. American Society of Clinical Oncology. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009, 27:6251-6266.
2. Azzoli C.G., Temin S., Aliff T., Baker S., Brahmer J., Johnson D.H., et al. 2011 focused update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2011, (September). [Epub ahead of print].
3. Felip E., Gridelli C., Baas P., Rosell R., Stahel R., Panel Members Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010. Ann Oncol 2011, 22:1507-1519.
4. National Comprehensive Cancer Network-Clinical Practice Guidelines in Oncology. Non-small-cell lung cancer. Version 3.2011 [last accessed 18.07.2011]. http://www.nccn.org/.
5. de Marinis F., Rossi A., Di Maio M., Ricciardi S., Gridelli C. Treatment of advanced non-small-cell lung cancer: Italian Association of Thoracic Oncology (AIOT) clinical practice guidelines. Lung Cancer 2011, 73:1-10.
6. Gridelli C., Maione P., Rossi A., Ferrara M.L., Bareschino M., Schettino C., et al. Potential treatment option after first-line chemotherapy for advanced NSCLC: maintenance treatment or early second-line?. Oncologist 2009, 14:137-147.
7. Fidias P.M., Dakhil S.R., Lyss A.P., Loesch D.M., Waterhouse D.M., Bromund J.L., et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2009, 27:591-598.
8. Fidias P.M. Docetaxel maintenance treatment in advanced NSCLC-Results of a phase III Trial. Presented at 2008 Chicago Multidisciplinary Symposium in Thoracic Oncology 2008.
9. Ciuleanu T., Brodowicz T., Zielinski C., Kim J.H., Krzakowski M., Laack E., et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009, 374:1432-1440.
10. Belani C.P., Brodowicz T., Ciuleanu T., Kim J.H., Krzakowski M., Laack E., et al. Maintenance pemetrexed plus best supportive care (BSC) versus placebo plus BSC: a randomized phase III study in advanced non-small cell lung cancer. J Clin Oncol 2009, 27:18s. [Suppl.; abstr CRA8000].
11. Westeel V., Quoix E., Moro-Sibilot D., Mercier M., Breton J.L., Debieuvre D., et al. French Thoracic Oncology Collaborative Group (GCOT). Randomized study of maintenance vinorelbine in responders with advanced non-small-cell lung cancer. J Natl Cancer Inst 2005, 97:499-506.
12. Brodowicz T., Krzakowski M., Zwitter M., Tzekova V., Ramlau R., Ghilezan N., et al. Central European Cooperative Oncology Group CECOG. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial. Lung Cancer 2006, 52:155-163.
13. Belani C.P., Waterhouse D.M., Ghazal H., Ramalingam S.S., Bordoni R., Greenberg R., et al. Phase III study of maintenance gemcitabine (G) and best supportive care (BSC) versus BSC, following standard combination therapy with gemcitabine-carboplatin (G-Cb) for patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2010, 28:15s. [Suppl.; abstr 7506].
14. Perol M., Chouaid C., Milleron B.J., Gervais R., Barlesi F., Westeel V., et al. Maintenance with either gemcitabine or erlotinib versus observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy in advanced NSCLC: IFCT-GFPC 0502 phase III study. J Clin Oncol 2010, 28(15s). [Suppl.; abstr 7507].
15. Paz-Ares L.G., De Marinis F., Dediu M., Thomas M., Pujol J., Bidoli P., et al. PARAMOUNT: phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo plus BSC immediately following induction treatment with pem plus cisplatin for advanced nonsquamous non-small cell lung cancer (NSCLC). J Clin Oncol 2011, 29. [Suppl.; abstr CRA7510].
16. Gridelli C., de Marinis F., Pujol J., Reck M., Ramlau R., Parente B., et al. Safety, resource use, and quality of life results from PARAMOUNT: A phase III study of maintenance pemetrexed plus best supportive care (BSC) versus placebo plus BSC immediately following induction treatment with pemetrexed-cisplatin for advanced NSCLC. Presented at 14th World Conference on Lung Cancer 2011.
17. Barlesi F., de Castro J., Dvornichenko V., Kim J.H., Pazzola A., Rittmeyer A., et al. AVAPERL (MO22089): final efficacy outcomes for patients with advanced non-squamous non-small cell lung cancer randomised to continuation maintenance with bevacizumab or bevacizumab+pemetrexed after first-line bevacizumab-cisplatin-pemetrexed treatment. Presented at 2011 ECCO-ESMO European Multidisciplinary Cancer Congress. Eur J Cancer 2011, [47 (Suppl. 2): abstract 34LBA].
18. Cappuzzo F., Ciuleanu T., Stelmakh L., Cicenas S., Szczésna A., Juhász E., et al. SATURN investigators. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010, 11:521-529.
19. Miller V.A., O'Connor P., Soh C., Kabbinavar F. for the ATLAS Investigators; A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 2009, 27:18s. [Suppl.; abstr LBA8002].
20. Brugger W., Triller N., Blasinska-Morawiec M., Curescu S., Sakalauskas R., Manikhas G.M., et al. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer. J Clin Oncol 2011, 29:4113-4120.
21. Coudert B., Ciuleanu T., Park K., Wu Y.L., Giaccone G., Brugger W., et al. SATURN Investigators. Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy. Ann Oncol 2011, May 24 [Epub ahead of print].
22. Kabbinavar F.F., Miller V.A., Johnson B.E., O'Connor P.G., Soh C. ATLAS Investigators; Overall survival (OS) in ATLAS, a phase IIIb trial comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy (chemo) with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 2010, 28(15s). [Suppl.; abstr 7526].
23. Kelly K., Chansky K., Gaspar L.E., Albain K.S., Jett J., Ung Y.C., et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol 2008, 26:2450-2456.
24. Takeda K., Hida T., Sato T., Ando M., Seto T., Satouchi M., et al. Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small-cell lung cancer: results of a west Japan thoracic oncology group trial (WJTOG0203). J Clin Oncol 2010, 28:753-760.
25. Zhang L., Shenglin M., Song X., Han B., Cheng Y., Huang C., et al. Efficacy, tolerability, and biomarker analyses from a phase III, randomized, placebo-controlled, parallel group study of gefitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC; INFORM; C-TONG 0804). J Clin Oncol 2011, 29. [Suppl.; abstr LBA7511].
26. Sandler A., Gray R., Perry M.C., Brahmer J., Schiller J.H., Dowlati A., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355:2542-2550.
27. Reck M., von Pawel J., Zatloukal P., Ramlau R., Gorbounova V., Hirsh V., et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL. J Clin Oncol 2009, 27:1227-1234. [Erratum in: J Clin Oncol 2009;27:2415].
28. Pirker R., Pereira J.R., Szczesna A., von Pawel J., Krzakowski M., Ramlau R., et al. FLEX Study Team. Cetuximab plus chemotherapy in patients with advanced non-small cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009, 373:1525-1531.
29. Lynch T.J., Patel T., Dreisbach L., McCleod M., Heim W.J., Hermann R.C., et al. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced nonsmall-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol 2010, 28:911-917.
30. Pirker R., Paz-Ares L., Eberhardt W., Krzakowski M., Störkel S., Heeger S., et al. Epidermal growth factor receptor (EGFR) expression as a predictor of survival for first-line chemotherapy plus cetuximab in FLEX study patients with advanced non-small cell lung cancer (NSCLC). WCLC 2011, [abstract].
31. Johnson K.R., Ringland C., Stokes B.J., Anthony D.M., Freemantle N., Irs A., et al. Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis. Lancet Oncol 2006, 7:741-746.
32. Zhang X., Zang J., Xu J., Bai C., Qin Y., Liu K., et al. Maintenance therapy with continuous or switch strategy in advanced non-small cell lung cancer: a systematic review and meta-analysis. Chest 2011, 140:117-126.
33. Behera M., Owonikoko T.K., Chen Z., Kono S.A., Khuri F.R., Belani C.P., et al. Single-agent maintenance therapy for advanced-stage non-small cell lung cancer: a meta-analysis. J Clin Oncol 2011, 29. [Suppl.; abstr 7553].
34. Des Guetz G., Uzzan B., Chouahnia K., Nicolas P., Perol M., Morere J.F. Is there a benefit to maintenance therapy after first line chemotherapy in advanced non-small cell lung cancer-a systematic review with meta-analysis. Abstract Book, 2011 European Multidisciplinary Cancer Congress: S593. Eur J Cancer 2011, 47(Suppl. 1). [abstr. 9005].